Viral vector vaccines

Over the past two years, the SARS-CoV-2 pandemic has highlighted the impact that emerging pathogens can have on global health. The development of new and effective vaccine technologies is vital in the fight against such threats. Viral vectors are a relatively new vaccine platform that relies on reco...

Descripción completa

Detalles Bibliográficos
Autores principales: McCann, Naina, O’Connor, Daniel, Lambe, Teresa, Pollard, Andrew J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd. 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612401/
https://www.ncbi.nlm.nih.gov/pubmed/35643023
http://dx.doi.org/10.1016/j.coi.2022.102210
_version_ 1784819765977546752
author McCann, Naina
O’Connor, Daniel
Lambe, Teresa
Pollard, Andrew J
author_facet McCann, Naina
O’Connor, Daniel
Lambe, Teresa
Pollard, Andrew J
author_sort McCann, Naina
collection PubMed
description Over the past two years, the SARS-CoV-2 pandemic has highlighted the impact that emerging pathogens can have on global health. The development of new and effective vaccine technologies is vital in the fight against such threats. Viral vectors are a relatively new vaccine platform that relies on recombinant viruses to deliver selected immunogens into the host. In response to the SARS-CoV-2 pandemic, the development and subsequent rollout of adenoviral vector vaccines has shown the utility, impact, scalability and efficacy of this platform. Shown to elicit strong cellular and humoral immune responses in diverse populations, these vaccine vectors will be an important approach against infectious diseases in the future.
format Online
Article
Text
id pubmed-9612401
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-96124012022-10-28 Viral vector vaccines McCann, Naina O’Connor, Daniel Lambe, Teresa Pollard, Andrew J Curr Opin Immunol Review Over the past two years, the SARS-CoV-2 pandemic has highlighted the impact that emerging pathogens can have on global health. The development of new and effective vaccine technologies is vital in the fight against such threats. Viral vectors are a relatively new vaccine platform that relies on recombinant viruses to deliver selected immunogens into the host. In response to the SARS-CoV-2 pandemic, the development and subsequent rollout of adenoviral vector vaccines has shown the utility, impact, scalability and efficacy of this platform. Shown to elicit strong cellular and humoral immune responses in diverse populations, these vaccine vectors will be an important approach against infectious diseases in the future. Published by Elsevier Ltd. 2022-08 2022-05-25 /pmc/articles/PMC9612401/ /pubmed/35643023 http://dx.doi.org/10.1016/j.coi.2022.102210 Text en © 2022 Published by Elsevier Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review
McCann, Naina
O’Connor, Daniel
Lambe, Teresa
Pollard, Andrew J
Viral vector vaccines
title Viral vector vaccines
title_full Viral vector vaccines
title_fullStr Viral vector vaccines
title_full_unstemmed Viral vector vaccines
title_short Viral vector vaccines
title_sort viral vector vaccines
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9612401/
https://www.ncbi.nlm.nih.gov/pubmed/35643023
http://dx.doi.org/10.1016/j.coi.2022.102210
work_keys_str_mv AT mccannnaina viralvectorvaccines
AT oconnordaniel viralvectorvaccines
AT lambeteresa viralvectorvaccines
AT pollardandrewj viralvectorvaccines

Ejemplares similares